CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Dr. Colli is graduated in Medicine from Universidade de São Paulo (USP) in 2007, received his Ph.D. in Medical Sciences from Universidade de São Paulo in 2012, and was Medical Oncology Fellow until 2014 at Ribeirao Preto University Hospital (USP). He was Postdoc at National Cancer Institute (NIH) between 2013 and 2019. Currently, Dr. Colli is Assistant Professor of Medical Oncology Ribeirão Preto Medical School (USP) and Head of the Medical Oncology Service. Main research interest on molecular oncology, genitourinary cancers (mainly renal cancer), cancer germline susceptibility, immunotherapy, biomarkers, and computational clinical oncology. It was awarded with the Royal Society-Newton Advanced Fellowship in 2020. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Genetic variability plays a fundamental role in the development of cancer. Understanding this variability is essential to identify specific risk factors and develop precision medicine strategies that can offer more effective approaches for prevention and treatment. This project aims to evaluate the impact of variation by assessing the influence of polygenic scores related to treatment res…
Cell and tissue biology have been the focus of study for several centuries, aiming to understand the organization, structure, and function of cells in healthy and pathological tissues. During this period, numerous discoveries revolutionized this area, providing crucial molecular information to understand the relationship between tissue organization and cellular processes. Currently, genom…
Genome-wide association studies (GWAS) are an important tool for the characterization of the genetic architecture of cancer susceptibility, and a key step towards understanding the process of cancer development. Each susceptibility region explains only a small fraction of cancer risk, but the aggregation of those regions allows us to understand a significant part of the heritability, usin…
(Only some records are available in English at this moment)
Renal cell carcinoma (RCC) represents 2 to 3% of cancers worldwide, and is among the top ten most diagnosed, with a higher incidence in Western Countries. Among these, clear cell renal carcinoma (CCRcc) is the predominant histology seen, corresponding to 85% of cases. Treatment is with targeted therapy against vascular endothelial growth factor (VEGF) and with new immunotherapeutic agents…
Introduction: Breast cancer is currently the second cause of death in women in Brazil. Due to its relevance as a public health problem, identification of risk factors, including genetic alterations, may impact prevention, diagnosis and treatment of breast cancer. Among these, clonal mosaicism, defined as the presence of new cellular clones of somatic origin, has been studied in several tu…
Renal cell carcinoma (RCC) represents 2 to 3% of cancers worldwide, and is among the top ten most diagnosed, with a higher incidence in Western Countries. Among these, clear cell renal carcinoma (CCRcc) is the predominant histology seen, corresponding to 85% of cases. Treatment is with targeted therapy against vascular endothelial growth factor (VEGF) and with new immunotherapeutic agents…
Renal cancer is the seventh most common type of cancer and shows a growing increase in the number of new cases, especially in Brazil. GWAS (Genome-Wide Association Study) studies have been applied to identify single nucleotide polymorphisms (SNPs) in chromosomal regions at risk for the development of this disease. From such studies, 13 different risk regions have been identified for renal…
Renal cell carcinoma (RCC) accounts for 2 to 3% of all cancer cases globally, primarily affecting Western countries. Among RCC subtypes, clear cell renal carcinoma (ccRCC) represents approximately 85% of cases. Current treatment strategies predominantly involve targeting vascular endothelial growth factor (VEGF) and employing novel immunotherapeutic agents. Notably, immune checkpoint inhi…
Cancer is one of the most common causes of death in the world. Renal Carcinoma (RCC) is one of the ten main frequent types of Cancer, with an increasing number of new cases. Clear Cell Renal Carcinoma (ccRCC) is the most frequent subtype, responsible for about 75% of the cases. GWAS (Genome-Wide Association Study) is used for germline susceptibility discovery and has identified 13 regions…
Kidney cancer is responsible for more than 400,000 new diagnoses and 175,000 deaths annually. The most common form of this cancer is the Renal Cell Carcinoma - RCC-, which comprises a heterogeneous group of tumors originated by the epithelial cells of the renal tubules, the main subtype being the Clear Cell Carcinoma - ccRCC. The treatment of the RCC has undergone major changes over the p…
(Only some records are available in English at this moment)
Renal carcinoma (RCC) is one of the ten most frequent types of cancer, with an increasing number of new cases. Clear Cell Renal Carcinoma (ccRCC) is the most frequent subtype, responsible for about 75% of the cases. The SWI/SNF Complex acts in chromatin remodeling, modulating the expression of several genes involved in cell proliferation and immune response. SWI/SNF Complex is composed of…
Renal cell carcinoma (RCC) accounts for 2-3% of all cancers worldwide and is among the top ten most diagnosed malignancies, with higher incidence rates observed in Western countries. Among the RCC subtypes, clear cell renal cell carcinoma (ccRCC) is the predominant histology, representing 85% of cases. Treatment typically involves targeted therapies against vascular endothelial growth fac…